Prakt. lékáren. 2016; 12(3): 102-104 | DOI: 10.36290/lek.2016.023

Pharmacogenetics in practice of a clinical pharmacologist and a pharmacist

Olga Bartošová1, Ondřej Slanař1, Irena Netíková1
1 Farmakologický ústav 1. LF UK a VFN, Karlova univerzita v Praze a Oddělení klinické farmakologie a farmacie,

Pharmacogenetics is the field that studies the impact of the genetic variability of a patient on the effectiveness and side effects

of pharmacotherapy. This field is the basis for personalized medicine. Genotyping of patients may determine the choice and

dosage of a drug with respect to the prevention of toxicity and prediction of pharmacotherapeutic effect. The aim of this article

is to describe the importance of pharmacogenetics in the practice of a pharmacist-managed clinical service.

Keywords: pharmacogenetics, personalized medicine, genetic polymorphism, clinical pharmacist

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartošová O, Slanař O, Netíková I. Pharmacogenetics in practice of a clinical pharmacologist and a pharmacist. Praktické lékárenství. 2016;12(3):102-104. doi: 10.36290/lek.2016.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011; 68(2): 143-150. Go to original source... Go to PubMed...
    2. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature reviews. 2004; 5: 645-656. Go to original source... Go to PubMed...
    3. Šeda O, ŠedováL. Farmakogenomika a nutrigenomika: komplexni interakce genů s prostředim. Klin Farmako Farm. 2005; 9: 116-120.
    4. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine.Pharmacol Rev. 2011; 63(2): 437-459. Go to original source... Go to PubMed...
    5. Bakhouche H, Slanař O. Pharmacogenetics in clinical practice.Prague Med Rep. 2012; 113(4): 251-261. Go to original source... Go to PubMed...
    6. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006; 6(4): 223-227. Go to original source... Go to PubMed...
    7. Slanař O. Farmakogenomika - současnost, budoucnost, perspektiva. Klin Farmakol Farm. 2012; 26(3): 126-130.
    8. Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006; 16: 353-357. Go to original source... Go to PubMed...
    9. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6): 568-579. Go to original source... Go to PubMed...
    10. Slanar O, Bortlik M, Buzkova H, et al. Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 835-838. Go to original source... Go to PubMed...
    11. Slanar O, Chalupna P, Novotny A, et al. Fatal myelotoxicity after azathioprine treatment. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 661-665. Go to original source... Go to PubMed...
    12. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J.Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther. 2014; 141(1): 92-116. Go to original source... Go to PubMed...
    13. Cascorbi I. The promises of personalized medicine. Eur J Clin Pharmacol. 2010; 66(8): 749-754. Go to original source... Go to PubMed...
    14. Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385(9984): 2280-2287. Go to original source... Go to PubMed...
    15. Tan E, Lim EC, Teo Y. Molecular Pain. BioMed Central. 2009; 5: 32-40. Go to original source... Go to PubMed...
    16. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4): 354-362. Go to original source... Go to PubMed...
    17. Argalácsová S, Slanař O, Vítek P, et al. Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer. Physiol Res. 2015; 64(Suppl 4): 539-547. Go to original source...
    18. Rodríguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2015; 277(2): 201-217. Go to original source... Go to PubMed...
    19. Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2015; 54: 40-48. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.